175013-84-0
175013-84-0
Chemical Structure
Tonabersat
Synonym(s): SB-220453
- CAS No.: 175013-84-0
- Formula:C20H19ClFNO4
- Molecular Weight:391.82
IUPAC Name: N-((3S,4S)-6-acetyl-3-hydroxy-2,2-dimethylchroman-4-yl)-3-chloro-4-fluorobenzamide
InChIKey: XLIIRNOPGJTBJD-ROUUACIJSA-N
SMILES: O[C@@H]1C(C)(C)OC2=CC=C(C(C)=O)C=C2[C@@H]1NC(C3=CC(Cl)=C(F)C=C3)=O
Biological Activity: Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tonabersat | 99.88% | Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tonabersat-d6 | Tonabersat-d6 (SB-220453-d6) is deuterium labeled Tonabersat. Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Y-26763 | 99.7% | Y-26763 is a K+ channel opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K+ (KATP) channel activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Y-27152 | Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rilmakalim | Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K+ channels in the heart or other tissues. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tidembersat | Tidembersat (Example 4) is a benzopyran derivative that can be used in the research of a variety of CNS disorders and traumatic brain injury. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Celikalim | Celikalim (Way 120491) is an antihypertensive agent. Celikalim lowers blood pressure through opening potassium channelsin vascular smooth muscle. Celikalim can inhibit white thrombus formation. Celikalim is a potent potassium opener in dog model. Celikalim can be studied in thrombosis-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-191095 | 98.01% | BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-191095 hydrochloride | BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carabersat | 98.22% | Carabersat is a potent anticonvulsant agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NIP 142 | NIP-142 is a benzopyran derivative with multiple ion channel-blocking effects. NIP-142 selectively blocks the potassium ion channels enriched in atrial muscle, prolonging the effective refractory period (ERP) and action potential duration (APD) of the atrium, while having minimal effect on ventricular repolarization. NIP-142 also inhibits L-type/T-type calcium channels and sodium channels, further contributing to its anti-arrhythmic effect. NIP-142 shows significant efficacy in various atrial fibrillation models. NIP-142 can be used for research on arrhythmias. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Silberstein SD, et al. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalalgia. 2009 Nov;29 Suppl 2:17-27. [Content Brief]
- [2]. Chen Q, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 18;533(7604):493-8. [Content Brief]
- [3]. Kim Y, et al. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics. 2017 May 30. [Content Brief]
